Skip to main content

Adrenal Insufficiency

Nephrology
8
Pipeline Programs
3
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Neurocrine Biosciences
7 programs
5
2
Infacort®Phase 31 trial
Infacort®Phase 31 trial
ChronocortPhase 11 trial
Chronocort®Phase 11 trial
Hydrocortisone granulesPhase 11 trial
+2 more programs
Active Trials
NCT03051893Completed28Est. Apr 2012
NCT03343327Completed25Est. Apr 2018
NCT01960530Completed14Est. Nov 2014
+4 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
1
HydrocortisonePhase 21 trial
Evaluation of Children With Endocrine and Metabolic-Related ConditionsN/A1 trial
Evaluation of Patients With Endocrine-Related ConditionsN/A1 trial
Active Trials
NCT02769975Recruiting15,000Est. Dec 2030
NCT00005664Terminated1,588Est. Dec 2019
NCT01859312Completed8Est. Dec 2016
Takeda
TakedaTOKYO, Japan
1 program
hydrocortisonePHASE_2_32 trials
Active Trials
NCT03013166Completed3,000Est. Dec 2016
NCT00915343Completed64Est. Jan 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Neurocrine BiosciencesInfacort®
Neurocrine BiosciencesInfacort®
Takedahydrocortisone
Human BioSciencesHydrocortisone
Neurocrine BiosciencesInfacort®
Neurocrine BiosciencesChronocort®
Neurocrine BiosciencesInfacort
Neurocrine BiosciencesHydrocortisone granules
Neurocrine BiosciencesChronocort
Takedahydrocortisone
Human BioSciencesEvaluation of Children With Endocrine and Metabolic-Related Conditions
Human BioSciencesEvaluation of Patients With Endocrine-Related Conditions

Clinical Trials (12)

Total enrollment: 19,839 patients across 12 trials

Extension Study for Patients Entered Into Study Infacort 003

Start: Mar 2016Est. completion: Aug 201818 patients
Phase 3Completed

Treatment of Adrenal Insufficiency in Children

Start: Mar 2015Est. completion: Jul 201624 patients
Phase 3Completed
NCT00915343Takedahydrocortisone

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Start: Aug 2007Est. completion: Jan 200964 patients
Phase 2/3Completed

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

Start: May 2013Est. completion: Dec 20168 patients
Phase 2Completed

A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects

Start: Apr 2018Est. completion: Jul 201851 patients
Phase 1Completed

A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects

Start: Feb 2018Est. completion: Apr 201825 patients
Phase 1Completed

Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration

Start: May 2017Est. completion: Jul 201719 patients
Phase 1Completed
NCT01960530Neurocrine BiosciencesHydrocortisone granules

An Investigational Study of Hydrocortisone

Start: Oct 2013Est. completion: Nov 201414 patients
Phase 1Completed

A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

Start: Feb 2011Est. completion: Apr 201228 patients
Phase 1Completed
NCT03013166Takedahydrocortisone

THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone

Start: Sep 2016Est. completion: Dec 20163,000 patients
N/ACompleted
NCT02769975Human BioSciencesEvaluation of Children With Endocrine and Metabolic-Related Conditions

Evaluation of Children With Endocrine and Metabolic-Related Conditions

Start: Jul 2016Est. completion: Dec 203015,000 patients
N/ARecruiting
NCT00005664Human BioSciencesEvaluation of Patients With Endocrine-Related Conditions

Evaluation of Patients With Endocrine-Related Conditions

Start: May 2000Est. completion: Dec 20191,588 patients
N/ATerminated

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 19,839 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.